Ratings Roche Holding AG Börse Stuttgart

Equities

RHO

CH0012032113

Delayed Börse Stuttgart Other stock markets 07:13:21 28/06/2019 pm IST			5-day change	1st Jan Change
245 ^EUR	-0.08%		-2.62%	+15.68%

11:33am	ROCHE HOLDINGS AG : Jefferies remains Neutral	ZD
10:16am	Roche shares boosted by good results in obesity treatment	CF

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is one of the best yield companies with high dividend expectations.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
With an enterprise value anticipated at 3.25 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ROCHE HOLDING AG	+15.68%	203B	-
ELI LILLY AND COMPANY	+35.01%	709B	C+
NOVO NORDISK A/S	+30.80%	595B	B
JOHNSON & JOHNSON	-2.60%	367B	C+
MERCK & CO., INC.	+20.83%	334B	B-
ABBVIE INC.	+5.69%	289B	C+
ASTRAZENECA PLC	+14.60%	239B	B+
NOVARTIS AG	+9.37%	211B	B-
AMGEN INC.	+10.77%	171B	C+
PFIZER, INC.	+0.10%	163B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes